Skip to main content

Halaven Side Effects

Generic name: eribulin

Medically reviewed by Drugs.com. Last updated on Sep 6, 2023.

Note: This document contains side effect information about eribulin. Some dosage forms listed on this page may not apply to the brand name Halaven.

Applies to eribulin: intravenous solution.

Serious side effects of Halaven

Along with its needed effects, eribulin (the active ingredient contained in Halaven) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking eribulin:

More common

Incidence not known

Other side effects of Halaven

Some side effects of eribulin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to eribulin: intravenous solution.

Hematologic

Very common (10% or more): Neutropenia (up to 82%), anemia (up to 58%)

Very common (10% or more): Urinary tract infection (up to 10%)

Uncommon (0.1% to 1%): Dysuria, hematuria, proteinuria, hematuria, leukopenia, lymphopenia[Ref]

In one study, grade 3 neutropenia occurred in 28% of patients, 29% experience grade 4 neutropenia, and 5% of patients experienced febrile neutropenia. Dose reductions due to neutropenia occurred in 12% of patients and discontinuation was required in less than 1% of patients. Grade 3 or greater thrombocytopenia was reported in 1% of patients. Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor was used in 19% of patients treated with this drug.[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (up to 35%)

Common (1% to 10%): Dysgeusia, dizziness, hypoesthesia, lethargy, neurotoxicity, polyneuropathy, peripheral sensory neuropathy, paresthesia[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 35%), constipation (up to 25%), diarrhea (up to 18%), vomiting (up to 18%)

Common (1% to 10%): Abdominal pain, stomatitis, dry mouth, dyspepsia, gastroesophageal reflux disease, mouth ulceration, mucosal inflammation, abdominal distension

Postmarketing reports: Pancreatitis[Ref]

Cardiovascular

Common (1% to 10%): QT prolongation, tachycardia, peripheral edema[Ref]

Dermatologic

Very common (10% or more): Alopecia (up to 45%)

Common (1% to 10%): Rash, pruritus, nail disorder, night sweats, palmar plantar erythrodysesthesia, dry skin, erythema, hyperhidrosis[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (up to 10%)

Uncommon (0.1% to 1%): Dysuria, hematuria, proteinuria

v[Ref]

Hepatic

Common (1% to 10%): Alanine aminotransferase increased, aspartate aminotransferase increased, gamma glutamyl transferase increased, hyperbilirubinemia[Ref]

Metabolic

Very common (10% or more): Weight decreased (up to 21%), anorexia (up to 20%)

Common (1% to 10%): Hypokalemia[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia/Myalgia (up to 22%), back pain (up to 16%), bone pain (up to 12%), pain in extremity (up to 11%)

Common (1% to 10%): Muscle spasms, musculoskeletal pain, musculoskeletal chest pain[Ref]

Ocular

Common (1% to 10%): Lacrimation increased, conjunctivitis[Ref]

Other

Very common (10% or more): Asthenia/Fatigue (up to 54%), pyrexia (up to 21%)

Common (1% to 10%): Disseminated intravascular coagulation, oral herpes, mucosal inflammation, hot flushes, pain, chills, peripheral neuropathy, headache

Frequency not reported: Tinnitus[Ref]

Psychiatric

Very common (10% or more): Headache

Common (1% to 10%): Insomnia, depression[Ref]

Respiratory

Very common (10% or more): Dyspnea (up to 16%), cough (up to 14%)

Rare (less than 0.1%): Upper respiratory tract infection, nasopharyngitis, rhinitis

Frequency not reported: Oropharyngeal pain, epistaxis, rhinorrhea[Ref]

Immunologic

Very common (10% or more):

Common (1% to 10%): Oral candidiasis, influenza-like illness, mucosal inflammation

Postmarketing reports: Pneumonia, sepsis/neutropenic sepsis[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Pharmaceutical Society of Australia. APPGuide online. Australian prescription products guide online. http://www.appco.com.au/appguide/default.asp 2006.

3. Product Information. Halaven (eribulin). Eisai Inc. 2010.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.